SHAHNAZ ALI: Open Payments
NPI 1922020478 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,580 in 107 payments from 36 companies in 2025. Trend: 2023 $1,741 · 2024 $1,838 · 2025 $2,580
Food & beverage: $2,580
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 11 | $243 |
| ABBVIE INC. | 7 | $206 |
| Lundbeck LLC | 4 | $180 |
| UCB, Inc. | 3 | $176 |
| Neurocrine BioSciences, Inc. | 3 | $170 |
| GlaxoSmithKline, LLC. | 12 | $164 |
| Teva Pharmaceuticals USA, Inc. | 6 | $141 |
| Axsome Therapeutics, Inc. | 2 | $132 |
| Novo Nordisk Inc | 5 | $88 |
| Astellas Pharma US Inc | 4 | $85 |
Products named: REXULTI, Nayzilam, VRAYLAR, INGREZZA, TRELEGY ELLIPTA, AUSTEDO XR, Auvelity, Veozah.
Industry payments across MI — which companies pay providers there.
